Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heliox21 for post-extubation respiratory support
NCT01498432Phase 4Unknown
- Sponsor
- University College London
- Start
- Jan 2012
- Primary completion
- Jan 2013
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of heliox21 in Respiratory Insufficiency (RI) (2 arms), sponsored by University College London. Primary endpoint: Frequency to Tidal Volume Ratio at 4 hours. Status: unknown.
02
Drugs
heliox21
03
Conditions
Respiratory Insufficiency (RI)
Beyond the preview
Go deeper on NCT01498432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01498432.